

Eluminex Biosciences, an Ophthalmology-Focused Biotechnology Company, Announces Closing of \$50 Million Series A Financing

- Proceeds to fund development of novel and best-in-class therapeutics for eye diseases
- Charles Semba, MD, joins the company to serve as Chief Medical Officer

Shanghai, China, Nov. 20, 2020 – Eluminex Biosciences Limited (Eluminex), an ophthalmic biotechnology company committed to the discovery and development of first-in-class and/or best-in-class therapies, today announced the completion of a \$50 million (USD) Series A Financing co-led by Lilly Asia Ventures, GL Ventures (venture capital arm of Hillhouse Capital), and Quan Capital. The Eluminex headquarters and research and development center are located in Suzhou Industrial Park; the business center is based in Shanghai, and future plans include establishing a global clinical and registration center in the San Francisco Bay Area.

“We greatly appreciate the profound level of support and trust from three global investors,” said Jinzhong Zhang, PhD, Co-Founder, Chairman, and Chief Executive Officer. “With these proceeds, our goal is to build an innovative pipeline addressing critical unmet medical needs in vision-threatening diseases for patients worldwide. Additionally, we are pleased to have three world-renowned professors of ophthalmology as members of our Scientific Advisory Board: Quan Dong Nguyen, MD, MSc (Stanford University), Zuguo Liu, MD, PhD (Xiamen University), and Xiaodong Sun, MD, PhD (Shanghai Jiao Tong University). We are grateful for their significant contributions in helping us develop our pipeline programs.”

The company also announced that Charles Semba, MD, has joined Eluminex as Chief Medical Officer (CMO). Dr. Semba is an internationally recognized leader in ophthalmic drug development. He has served as CMO in three prior ophthalmic companies: SARcode Bioscience (acquired by Shire/Takeda), ForSight VISION5 (acquired by Allergan), and Graybug Vision (NASDAQ: GRAY). He has held senior leadership roles as Vice President Ophthalmic Medicine at Shire/Takeda and Ophthalmology Group Head at Genentech. Dr. Semba led the clinical development of ranibizumab (LUCENTIS®), the first global blockbuster anti-VEGF agent to reverse blindness in wet age-related macular degeneration and lifitegrast (XIIDRA®), the first novel agent for the treatment of both signs and symptoms of dry eye disease; XIIDRA® was acquired by Novartis for over \$5 billion (USD).

Regarding the success of this financing, all parties have expressed their confidence and expectations for the new company. “Closing Series A financing is indeed a major milestone. The leadership at Eluminex should be congratulated for this impressive achievement amidst current global events.” commented Dr. Nguyen, Professor of Ophthalmology at the Byers Eye Institute, Stanford University. “Such financial success and security demonstrate the trusts that the company has earned from the investment community in Eluminex’s research and development therapeutic plans to

preserve and enhance vision for patients with devastating ocular diseases worldwide.”

“Driven by an aging population and overuse of eyes in various ages, the ophthalmic market is seeing huge unmet needs for new products. The team’s solid track record and rich experience in ophthalmic drug development enables the company to develop innovative therapies not only for China but for the global market. We are thrilled and honored to join hands with this seasoned team and partner with reputable investors from the very beginning,” said Stephen Lin, Partner at Lilly Asia Ventures.

“The founding team of Eluminex Biosciences has rich experience in drug development and innovation with great potential in the future. Hillhouse will help Eluminex continue to innovate, research and develop leading ophthalmic disease treatment drugs, meeting the needs of a large number of patients, and continue to create social well-being,” said Michael Yi, Partner and Co-Chief Investment Officer of Hillhouse Capital Group.

“Quan Capital is committed to foster innovation and bring new solutions to patients with great unmet needs. We are pleased to co-lead the Series A round of Eluminex and are truly impressed by the stellar management team,” said Marietta Wu, Managing Director of Quan Capital. “We believe this team of seasoned industry veterans both globally and in China will build a leader in ophthalmology with accelerated development of novel therapeutics. Quan looks forward to working closely with the team and contributing our local resources and global networks.”

About Eluminex Biosciences

Eluminex was established in February 2020 with the commitment to leading the development of novel therapeutics for the benefit of patients with vision-threatening eye diseases worldwide. Co-Founders, Dr. Jinzhong Zhang and Dr. Zhenze John Hu, have assembled a top tier management team with significant ophthalmic drug development experience, aiming to build a robust and sustainable innovative ophthalmic pipeline to tackle the unmet clinical needs. For detailed information contact Zhenze John Hu at john.hu@eluminexbio.com

About Lilly Ventures Asia

Lilly Asia Ventures (LAV) is a leading biomedical venture capital firm founded in 2008, with offices in Shanghai, Hong Kong, and Menlo Park. LAV’s vision is to become the trusted partner for exceptional entrepreneurs seeking smart capital and to build great companies developing breakthrough products that can treat diseases and improve human health. For more information, visit www.lillyasiaventures.com.

About GL Ventures

GL Ventures focuses on early-stage innovative companies in healthcare, software services, consumer Internet, emerging consumer brands and services. The GL Ventures team is passionate about partnering with visionary entrepreneurs to create industry leaders that stand the test of time. GL Ventures is the early stage affiliate of Hillhouse Capital, and we have been investing with innovators across the world since 2005. We were one of the earliest investors into some of the largest global companies today, including BeiGene, Zoom, Meituan, JD, Woowa Brothers and many more.

About Quan Capital

Quan Capital (Quan) is a life sciences venture capital firm with strong China expertise and global capabilities. Quan discovers, incubates, and grows next-generation life science companies in early and growth stage, worldwide. Their portfolio companies pioneer differentiated therapies and enabling technologies to address major human diseases with high unmet medical needs. With offices in Shanghai, Palo Alto and Boston, Quan's investment professionals combine their strong expertise in both science and business with their diverse experiences in global drug development and healthcare investments, and leverage their broad network worldwide to help maximize the company's value across geographies and development stages. For more information, visit www.quancapital.com.

专注眼科创新药研发的典晶生物完成五千万美元 A 轮融资

- 资金将用于研发首创和同类最佳的眼科疾病疗法
- Charles Semba 博士加入公司，担任首席医学官

2020 年 11 月 20 日，中国上海 – 一家致力于研发全球创新疗法的眼科生物技术公司，典晶生物医药科技（苏州）有限公司（典晶生物），今天宣布完成五千万美元的 A 轮融资。此次融资由礼来亚洲基金，高瓴创投和泉创资本共同领投。典晶生物总部和研发中心位于苏州工业园区，在上海设有商务中心，并计划在美国旧金山湾区设立国际临床和注册中心。

共同创始人，董事长和首席执行官张金忠博士表示：“我们非常感谢三家国际知名投资机构的支持和信任。公司将利用这些资金建立全球创新的研究管线和核心眼药创新技术平台，以满足中国和全球患者对于眼部疾病的医疗需求。同时我们很高兴聘请到三位国际著名的眼科专家，斯坦福大学的 Quan Dong Nguyen 教授，厦门大学的刘祖国教授和上海交通大学的孙晓东教授为典晶生物首届科学顾问委员会的成员，并感谢他们在制定公司战略和研发管线方面的建议和帮助。”

典晶生物由礼来亚洲基金与两位海归共同创办。张金忠博士是北京大学和日本京都大学联合培养的理学博士，曾是美国 Case Western Reserve 大学医学院的眼科学助理教授和美国国立卫生研究院眼科研究所资助项目的首席研究员，先后在美国博士伦、日本参天制药和最近在纳斯达克上市的美商眼科初创公司 Graybug Vision 担任高级领导职位，参与了多个上市眼科创新产品的研发。胡珍泽博士先后在中国药科大学和美国密西根大学获得药学本科和博士学位，二十多年来一直专注于眼科领域，在国内外眼科产品的研发、临床需求、国际法规、技术转让以及市场分析方面具有丰富的经验。

公司同时宣布，Charles Semba（仙波）博士应邀加入典晶生物，并担任首席医学官。仙波博士是国际著名的眼科新药研发专家，之前曾在三家眼科公司担任首席医学官：SARcode Bioscience（被 Shire / Takeda 收购），ForSight VISION5（被艾尔建收购）和 Graybug Vision（纳斯达克：GRAY）。他还曾在 Shire / Takeda 担任眼科医学副总裁，在 Gegentech 担任眼科临床开发部门负责人。仙波博士成功领导了全球首个治疗湿性年龄相关性黄斑病变的重磅抗体药雷珠单抗（LUCENTIS）和首个同时改善症状和体征的新型干眼药 XIIDRA 的临床开发。

公司核心团队还包括两位分别在眼科转化医学和临床管理方面卓有成就的成员。申维勇博士是在中国和澳大利亚接受过培训的眼科医生，在典晶生物担任研究副总裁；他有超过 25 年从事视网膜疾病的基础和转化研究的经验，在眼科学和神经科学领域发表了 90 余篇论文。李玫博士在典晶生物担任临床运营副总裁；她有 20 多年在国内从事临床试验管理的丰富经验，曾为艾尔建（中国）的多个进口眼科产品的临床研究和注册做出重要贡献。

关于此次成功的 A 轮融资，各方都表达了对新公司的信心和期望。刘祖国教授表示：“全球目前仍然有许多眼病的治疗不能满足病人的需求，一方面需要大力开展基础研究，找出其发病机制，同时更需要发现新的药物。典晶生物具有强大的药物开发团队，聚焦于眼科创新药物开发，这将会推动我国眼科创新药物的发展，为眼病患者带来福音与希望。”

礼来亚洲基金合伙人林亮表示：“我们非常荣幸有机会与张金忠博士和胡珍泽博士合作创办

典晶生物。团队集聚多位国际化兼本土化的创新眼药开发精英，其出众的研发经验令我们相信公司不仅能为中国而且能为全球市场开发创新的疗法。很高兴能从一开始就与这个资深的团队及业内顶尖投资机构携手合作，共同打造典晶生物。随着公司的起飞，我们期待典晶生物能成为创新眼药领域的画龙点睛之笔。”

高瓴资本联席首席投资官、高瓴创投生物医药及医疗器械负责人易诺青表示：“随着老龄化加重、生活方式改变、过度用眼增加和大众健康意识的提升，近年来国内眼部疾病发病率呈不断上升趋势，然而眼科药物研发技术要求高，且国内获批新药较少，国内患者有大量未被满足的需求。典晶生物创始团队拥有丰富的药品开发能力和持续创新能力，未来潜力巨大。高瓴将助力典晶生物持续创新，研究开发领先的眼科疾病治疗药品，满足大量患者未被满足的需求，不断创造社会福祉。”

泉创资本董事总经理巫荟博士表示：“泉创资本致力于通过促进创新为患者带来亟需的新兴疗法。我们很高兴共同领投典晶生物的 A 轮融资，公司出色的管理团队给我们留下了深刻的印象。我们相信，无论是全球还是中国，这支经验丰富的团队都将通过加快创新疗法的开发，成为眼科领域的领导者。泉创资本期待利用在中国和全球的资源与典晶生物紧密合作。”

关于典晶生物医药科技（苏州）有限公司

典晶生物 (Eluminex Biosciences Limited) 成立于 2020 年 2 月，是一家专注于眼科疾病的生物医药公司。典晶生物由一支经验丰富的团队领导，旨在建立创新和可持续发展的眼药产品管线，以解决未被满足的临床需求，惠及中国和全球眼部疾病的患者。公司总部和研发中心位于苏州工业园区，在上海设有商务中心，并计划在美国旧金山湾区设立国际临床和注册中心。如需了解更多信息，请通过 john.hu@eluminexbio.com 与胡珍泽博士联系。

关于礼来亚洲基金

礼来亚洲基金 (Lilly Asia Ventures, 简称 LAV) 是一家领先的生物医学风险投资公司，成立于 2008 年，在上海、香港和美国硅谷设有办事处。其愿景是成为寻求资本的杰出企业家的可靠合作伙伴，一起组建伟大的公司，开发能够治疗疾病和改善人类健康的突破性产品。请访问 www.lillyasiaventures.com，以了解更多的信息。

关于高瓴创投

高瓴创投是高瓴旗下专注于早期创新型公司的风险投资基金，主要专于生物医药及医疗器械、软件与硬科技、消费互联网及科技、新兴消费品牌及服务四大领域的风险投资。生物医药和医疗器械领域一直是高瓴的重点投资方向，十多年来，高瓴投资了 200 多家优秀的生物医药、医疗器械及医疗服务等企业。希望与企业一起，做时间的朋友，共同推动大健康领域企业的创新和发展，惠及更多患者。

关于泉创资本

泉创资本是一家专注于早期和成长阶段生命科学领域的创投基金。以创新为驱动，以科学和商业上的独特洞见为向导，在全球范围内寻找、创建、投资有快速发展前景的生命科学领军企业。其投资组合中的公司包括前沿的创新疗法、尖端的技术平台，以及能填补生态系统空白的行业佼佼者。泉创资本目前在上海，旧金山和波士顿设有办公室。凭借丰富的行业经验和深厚的业内资源，其专业投资人甄别和孵化下一代的优秀公司，并尽其所能，鼎力支持新兴医药科技企业的战略、运营和发展，在全球范围内辅助不同发展阶段的公司转型，帮助公司实现价值的最大化。请访问 www.quancapital.com，以了解更多的信息。